Contract analysis

I. IDENTIFICATION OF THE OUTSTANDING OFFICE ACTION On September 15, 2024, the United States Patent and Trademark Office mailed a Non-Final Office Action in the above-captioned application, U.S. Application No. 17/851,216 (hereinafter, the "Office Action"). Pursuant to 35 U.S.C. § 133 and 37 C.F.R. § 1.134, the shortened statutory period for response to the Office Action is three months from its mailing date. Accordin

II. STATEMENT OF THE EXTENSION REQUESTED Applicant hereby respectfully requests a three-month extension of time under 37 C.F.R. § 1.136(a) to respond to the Non-Final Office Action mailed September 15, 2024. The requested extension consists of three successive one-month extensions of time, as follows: (1) A first one-month extension of time, extending the response deadline from January 15, 2025 to February 15, 2025;

III. STATUTORY BASIS This request is made pursuant to 37 C.F.R. § 1.136(a), which provides that the time for filing a response to an Office Action may be extended, upon the filing of a petition therefor and the payment of the applicable fee(s), in increments of one month, up to a maximum of the six-month statutory period for response set forth in 35 U.S.C. § 133. Extensions of time under 37 C.F.R. § 1.136(a) are avai

IV. ENTITY SIZE CERTIFICATION Applicant, Solstice Biomedical Devices Ltd., hereby certifies that it qualifies as a small entity under 37 C.F.R. § 1.27 for the purpose of paying reduced patent fees in connection with the above-identified application. Solstice Biomedical Devices Ltd. is a private limited company incorporated under the laws of Ireland, with registered office at Unit 4, Liffey Innovation Campus, Parkgate

V. FEE TRANSMITTAL A. Fee Calculation The fees required for the requested three-month extension of time, calculated at the small-entity rate, are as follows: B. Payment Authorization The Director of the United States Patent and Trademark Office is hereby authorized to charge the total fees of $1,380.00 to Deposit Account No. 50-3917 of Calderwood & Harkness LLP maintained at the United States Patent and Trademark Off

VI. CONDITIONAL PETITION FOR EXTENSION OF TIME Should the United States Patent and Trademark Office determine that a greater or different extension of time fee is required than as set forth in Section V above — whether due to a change in the fee schedule, a recalculation of the applicable response period, a change in entity status, or any other reason — the Commissioner is hereby authorized to treat this paper as a p

VII. CERTIFICATE OF ELECTRONIC FILING I hereby certify that this Request for Extension of Time Under 37 C.F.R. § 1.136(a), together with the accompanying Fee Transmittal, is being filed electronically via the United States Patent and Trademark Office Patent Center electronic filing system on the date set forth below. The filing is directed to U.S. Application No. 17/851,216, Confirmation No. 4817, assigned to Art Uni

VIII. SIGNATURE Respectfully submitted, CALDERWOOD & HARKNESS LLP /Wendy Schultz/ Wendy Schultz Registration No.: 78,115 Associate, intellectual Property — Patent Prosecution Calderwood & Harkness LLP 600 Lexington Avenue, 22nd Floor New York, NY 10022 Telephone: (212) 848-6200 Facsimile: (212) 848-6201 Email: wschultz@calderwoodharkness.com Date: ________

IX. CUSTOMER NUMBER AND CORRESPONDENCE ADDRESS All correspondence related to this application should be directed to the following: Customer Number: 74291 Correspondence Address: Calderwood & Harkness LLP 600 Lexington Avenue, 22nd Floor New York, NY 10022 Attention: Wendy Schultz / Peter Vassiliev Matter No.: SBD-IP-2021-003

X. APPLICANT INFORMATION Applicant / Assignee of Record: Solstice Biomedical Devices Ltd. Unit 4, Liffey Innovation Campus Parkgate Street Dublin 8, D08 XR29 Ireland Companies Registration Office No. 647832 U.S. Subsidiary (for correspondence purposes): Solstice Biomedical Inc. 200 Chestnut Ridge Road, Suite 310 Woodcliff Lake, NJ 07677 Delaware File No.: 7291456 CERTIFICATE OF SERVICE / TRANSMISSION I hereby certify